title: Treatment of human monocyte-derived macrophages with a TNF alpha synthesis inhibitor prior to HIV1 infection: consequences on cytokine production and viral replication.
abstract: Human monocyte-derived macrophages (MDM) were infected with the viral strain HIV1/Ba-L and with the clinical isolates HIV1/DAS and HIV1/PAR. Kinetics of tumour necrosis factor alpha (TNF alpha) and interleukin-6 (IL6) production were investigated for 28 days after infection. At the early stages of infection we observed significant TNF alpha and IL6 secretion 2 to 10 h after infection, whatever the viral strain we used. During the late events of MDM infection, TNF alpha and IL6 were detected over 16 to 21 days following HIV1 infection, at the time of high viral replication. Pretreatment of MDM with a TNF alpha synthesis inhibitor, RP 55778, 4 h prior to HIV infection induced a modified cytokine pattern during the first ten hours of infection: TNF alpha production was totally inhibited despite comparable amounts of IL6. At the late phases of the cell culture, a decrease in magnitude of both viral and cytokine production as well as a delay in the appearance of reverse transcriptase activity and cytokine secretion peaks were observed in RP-55778-pretreated and HIV1-infected MDM cultures. Similar results were obtained after pretreatment of HIV1/DAS-infected MDM cultures with an anti-TNF alpha monoclonal antibody.
authors: Laboratoire de Neuropathologie expérimentale et Neurovirologie, CRSSA, DSV/DPTE, Institut Paris-Sud sur les Cytokines, Commissariat à l'Energie Atomique, Fontenay-aux-Roses, France.
authors: R
authors: R
authors: Le Naour
authors: H
authors: H
authors: Raoul
authors: A
authors: A
authors: Mabondzo
authors: Y
authors: Y
authors: Henin
authors: A
authors: A
authors: Bousseau
authors: D
authors: D
authors: Dormont
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015658:HIV Infections / Q000276:immunology* / Q000821:virology*; D015497:HIV-1 / Q000276:immunology / Q000502:physiology*; D006801:Humans; D066298:In Vitro Techniques; D015850:Interleukin-6 / Q000096:biosynthesis; D007700:Kinetics; D008264:Macrophages / Q000276:immunology* / Q000821:virology*; D009000:Monocytes / Q000276:immunology / Q000821:virology; D011725:Pyridines / Q000494:pharmacology; D013844:Thiazoles / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000276:immunology; D014779:Virus Replication
chemical_list: D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D011725:Pyridines; D013844:Thiazoles; D014409:Tumor Necrosis Factor-alpha; C052520:3-(3-pyridinyl)-1H,3H-pyrrolo(1,2-c)thiazole-7-carboxamide